unknown by unknown
CONCLUSION:  The majority of these patients had bulky disease which 
could not have received immediate RT with curative intent, on account of 
risk of spinal cord damage, even with concomitant chemotherapy.  Induction 
chemotherapy allows down-staging of disease and we feel should not be 
discontinued, though our protocol now also includes concomitant cis-or 
carboplatin with RT. 
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THE EFFECT OF PHYTOESTROGENS ON PROSTATE CANCER 
CELLS IN VITRO.
Colm Morrissey*, R. William G. Watson and John M. Fitzpatrick 
Department of Surgery, Conway Institute of Biomolecular and Biomedical 
Research, University College Dublin, Mater Misericordiae Hospital, Dublin, 
Ireland. 
Androgen independence represents the most non-treatable form of prostate 
cancer. In the past, advanced stage prostate cancer was treated using the 
synthetic oestrogen diethylstilbestrol, reducing serum testosterone levels by 
negative feedback on the pituitary-gonadal axis. Phytoestrogens are non-
steroidal plant-derived compounds possessing oestrongenic activity. We 
hypothesized that these compounds would increase the effects of the anti-
androgens in their ability to induce cell death. PC-3 (malignant androgen 
independent) LNCaP (malignant androgen sensitive) and RWPE-1 (benign 
androgen sensitive) cells were treated with or without an extract of 
Belacanda Chinensis, two purified phytoestrogens derived from this extract; 
irigenin and tectorigenin and the anti-androgen biclutamide, and assessed for 
their effects on cell number and apoptosis using the crystal violet assay and 
propidium iodide DNA staining assays, respectively. The phytoestrogens (50-
100 µ M) and biclutamide (10-50 µ M) alone decrease cell number in all three 
cell lines. When the phytoestrogens (50 µ M) are used in combination with 
biclutamide (10 µ M) there is no statistical difference in the loss of cell 
number in the RWPE-1 and LNCaP cell lines. However, in the androgen 
insensitive PC-3 cell line all three phytoestrogens showed a statistically 
significant decrease in cell number when treated with all three compounds in 
conjunction with biclutamide with P values of 0.017, 0.023 and 0.049 for the 
extract, irigenin and tectorigenin respectively. The phytoestrogen effects are 
increased when used in combination with biclutamide in the PC-3 cell line. 
Biclutamide induced apoptosis in a dose dependent manner, but the 
phytoestrogens had no effect. These in vitro studies will lead to a better 
understanding of the mechanism of action of the phytoestrogens and their 
possible use in prostate cancer prevention or management. 
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A PHASE I/II STUDY OF GEMCITABINE (G) AND CISPLATIN (C) 
IN METASTATIC OR RELAPSED TRANSITIONAL CELL 
CARCINOMA IN AN OUTPATIENT SETTING. 
 Syed A. Hussain*
1, 2, Ian Geh
2, Peter Riley
2, Nicholas D. James
1, 2 Cancer 
Research UK Institute For Cancer Studies
1 Queen Elizabeth Hospital
2
Birmingham, United Kingdom 
Introduction: A randomised phase III trial of MVAC vs. GC (G 1000mg/m2 
d1, 8+15, C 70mg/m2 d2, 28 d cycle) (JCO 2000 17:3068-3077) showed that, 
with the same efficacy, GC had a better toxicity profile. The most important 
haematological toxicities of GC were noticed on d15 resulting in dose 
adjustments in 37% of cycles. To optimise drug delivery and minimise 
platinum related toxicity, we are exploring administration of GC on a 21 day 
cycle with G and C split between D1 and D8 in a phase I/II mixed dose 
escalation. Primary objectives are definition of maximum tolerated dose 
(MTD) and toxicity; secondary endpoints are response rate, progression free 
and overall survival. 
Methods: Patients with locally advanced, relapsed or metastatic disease are 
eligible. ECOG PS 0-2, adequate bone marrow, liver function, GFR > 
40mls/min. Planned dose escalation G/C 1000/35, 1100/35, 1200/35, 1200/45 
mg/m2 treated days 1 & 8 of a 21 day cycle.  
Results: 15 patients have been enrolled (9 M, 6 F, age 41-79, median 64 y); 
12 N+ disease, 8 M1 (1 bone, 1 lung plus bone, 1 lung plus liver, 1 liver, 3 
lung, 1 psoas and pre-sacral tumour deposit); 2 had previous cystectomy; 1 
had a open and close laparotomy, 5 had previous radical RT (2 synchronous 
chemoradiation); 2 previous CMV chemotherapy;   8/15 had GFR of 40-
60mls/min. Dose limiting toxicity (DLT) was haematological (Grade IV 
thrombocytopenia) and was reached at dose level 2. The extended phase II 
study is continuing at dose level 1 (1 level below the DLT) as per protocol. 
At dose level 1 there was 1 grade IV episode (GI perforation), toxicity was 
otherwise grade III (anaemia 1/4, neutropenia 1/4, thrombocytopenia 1/4). At 
dose level 2 more severe haematological toxicity was encountered (anaemia 
1/9, neutropenia 4/9 (1 grade IV), thrombocytopenia 5/9 (3 grade IV)) 
thereby defining the MTD. Non-haematological toxicity included 1 GI 
perforation and 1 GI bleed (both G IV). Of 55 cycles administered, we 
observed platelets <100 d15 in 22/55 cycles, neutrophils <0.5 or plat<50 in 
9/55 cycles; but only 2/55 cycles (in the same patient) were deferred at day 
21 for haematological toxicity. Renal functions have remained stable on this 
regimen. Median dose intensity delivered was 96% (Range 78% -100%).  
There were 2 early deaths (GI perforation on steroids as anti emetic; GI bleed 
on warfarin for DVT secondary to massive pelvic lymphadenopathy, found to 
have pyloric ulcer) and were not assessable for response but included in the 
efficacy analysis. Two patients are enrolled in the phase II study, 9 pts have 
undergone response assessment of which 3 had CR, 4 PR to give an interim 
overall response rate of 7/11 (64%) for the phase I part of the trial. 
Conclusion: The MTD of this split dose schedule has been defined and the 
regimen is deliverable on an outpatient basis without the need for inpatient 
hydration. The schedule has substantial activity even in pre-treated patients 
with renal function below that conventionally included in protocols with this 
combination and the phase II trial is ongoing. 
Key words: Bladder Cancer    Gemcitabine and Cisplatin    Out-patient 
treatment 
P101 
THE EFFECT OF COMBINATION GEMCITABINE AND 
PHOTODYNAMIC THERAPY ON CLONOGENIC SURVIVAL IN 
BLADDER CANCER CELL LINES IN VITRO 
C Briggs
1,2, JV Moore
2, NW Clarke
1
1Department of Urology, Hope Hospital, Salford 
2Paterson Institute for Cancer Research, Christie Hospital, Manchester 
Introduction 
Gemcitabine is a cytosine analogue, which has radiosensitising properties and 
antitumour activity in a variety of solid tumours.  Its effects in combination 
with photodynamic therapy have not previously been reported.  The aim of 
this study was to determine the effect of combination treatment with 
gemcitabine and aminolaevulinic acid-mediated photodynamic therapy (ALA 
PDT) in two related bladder TCC cell lines. 
Materials and Methods 
Two related bladder cancer cell lines were studied: the radioresistant parent 
line MGH-U1 and its radio-resistant clone, S40b.  Standard clonogenic 
assays were performed following treatment with ALA PDT alone (5mM 
ALA for 24 hours prior to PDT) or in combination with gemcitabine 
(0.01µ M +5mM ALA for 24 hours before PDT). 
Results 
Clonogenic survival assays showed that both cell lines were sensitive to PDT 
alone, though MGH-U1 was significantly more-so than S40b (p<0.001).  This 
was explained by a 4-fold greater level of protoporphyrin IX (PpIX) 
fluorescence in the MGH-U1 cell line.  Prior exposure to gemcitabine 
produced a 2-fold decrease in cell survival in the radio-resistant cell line, but 
caused the radiosensitive S40b cell line to become relatively resistant to PDT 
under the same conditions (p<0.001). 
Conclusions 
Gemcitabine increases the sensitivity of TCC to ALA PDT, but a differential 
effect is seen in radiosensitive and radio-resistant cells.  Work continues to 
establish mechanisms accounting for this response, but a role for combination 
treatment with radiosensitisers and PDT in superficial bladder cancer 
treatment is suggested.
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MANAGEMENT OF PATIENTS WITH ADVANCED GERM CELL 
TUMOURS (GCT): IS THERE A ROLE FOR POMB-ACE? 
N. Bhala, J. George, J.M. Coleman, C.R. Radstone, J.M. Horsman, B.W. 
Hancock, M.Q. Hatton, R.E. Coleman*. 
YCR Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, 
United Kingdom.
Aims Germ cell tumours (GCT) are the commonest malignancies in young 
men and overall survival has been increased with the introduction of 
cisplatin-based therapy.  Previous trials have indicated BEP (bleomycin, 
etoposide and cisplatin) as the optimum treatment, although some centres 
advocate the use of the alternating regimen POMB/ACE (cisplatin, 
vincristine, methotrexate, bleomycin & actinomycin D, cyclophosphamide 
and etoposide) in more advanced metastatic disease.  We undertook a study 
of patients treated at Weston Park Hospital, Sheffield (WPH) and 
retrospectively analysed the survival and management of this population. 
Methods  Patient information was retrieved using the Trent Testicular 
Tumour Registry and from patient notes.  This included all patients with 
Royal Marsden Hospital Stage II, III and IV disease and those with Stage I 
disease that relapsed.  These data were then used to produce survival curves 
and the different chemotherapy regimens used were compared with regard to 
efficacy and toxicity. 
Results 178 NSGCT and 71 seminoma patients were identified.  Survival 
curves yielded outcomes that were similar to the IGCCCG
1 classification for 
the NSGCT good (Five year survival 95% vs. 92%), and intermediate (5 year 
survival 82% vs. 80%) prognoses groups.  The survival of the poor prognosis 
group was markedly better at WPH (5 year survival 57% vs. 48%).  There 
was a higher frequency of severe side effects with POMB/ACE. 
Conclusions Survival and disease progression rates at this single institution 
were at least as good as those reported in the series published by IGCCCG
1
and better in the poor prognosis group.  In the latter, the principal difference 
is the use of the POMB/ACE chemotherapy regimen as opposed to the 
standard BEP regimen.  We would recommend a randomised comparison of 
BEP and POMB/ACE to validate this. 
1 International Germ Cell Cancer Collaborative Group. International Germ 
Cell Consensus Classification: A Prognostic Factor-Based Staging System 
for Metastatic Germ Cell Cancers. J Clin Oncol 1997; 15(2): 594-603. 
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TRENDS IN SURVIVAL OF PATIENTS DIAGNOSED WITH 
PRIMARY TESTICULAR TUMOURS IN LEICESTERSHIRE: A 15-
YEAR EXPERIENCE (1983 ￿ 1997)  
S.Santhanam*, M. Decatris, F.J.Madden. Dept. of Oncology, University 
Hospitals of Leicester. Leicester. 
AIM: A retrospective analysis of all primary Testicular tumour patients 
treated at the University hospitals of Leicester between 1983 and 1997.  
METHODS: 328 consecutive primary Testicular tumour patients (excluding 
lymphomas) diagnosed between 1983 and 1997 were included. Use of 
various treatment modalities, which influences the long-term treatment 
related sequelae and overall survival (OS) rates were analysed. To analyse 
the trends in survival, the 5-year OS of patients diagnosed between 1983 -
1990 (Cohort A) is compared with those diagnosed between 1991- 1997 
(Cohort B). Statistical computations were performed using StatViewﬁ for
Windows, (SAS Institute Inc., USA).  
RESULTS: Overall, 104 patients had primary chemotherapy (CT), 158 had 
primary radiotherapy (RT), [of these 9 had combined therapy (RT + CT)], 69 
were managed by active surveillance. Treatment data was missing for 6 
patients. With a mean follow-up period of 72 months (median 62 months), 
the 5-yr and 10-yr OS for all patients was 92% and 88% respectively.  The 5-
yr OS for Cohort A and Cohort B was 90% and 94% respectively (p >0.1). 
There were no significant differences in distribution of age, stage and 
histology between the two cohorts (p >0.26, >0.70, >0.66 respectively). The 
number of patients treated by primary CT, primary RT and active 
surveillance remained stable over this study period. (Cohort A: 33%, 41%, 
20%; Cohort B: 31%, 48%, 23%, respectively; p >0.62). The number of 
patients treated by BEP (Bleomycin, Etoposide, Cisplatin) regime did not 
vary during this period. (Cohort A: 82.97%; cohort B: 83.01%). But there 
was a significant reduction in the intensity of CT (mean CT cycles per 
patient, Cohort A: 4.7; Cohort B: 3.4; p < 0.01) and total dose of RT (patients 
receiving >30 Gy, Cohort A: 51%; Cohort B: 12% p< 0.001) administered 
during this period. 
CONCLUSION:  The survival rates are comparable to the national and 
international data available. [5-yr survival of patients diagnosed between 
1986-1990: Leicester 93%; England & Wales 91%; Scotland 92%, USA 
95%; and Europe (1985-89) 90%] (1). The trend towards a better 5-yr 
survival over this study period has been achieved with less intensive 
treatment regimens and this should minimise the incidence of long-term 
treatment related sequelae in these patients with highly curable tumours.  
(1) Coleman.1999. Cancer survival trends in England and Wales, 1971 - 
1995. Office for National Statistics. 
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CONFORMAL RADIOTHERAPY FOR PROSTATE CANCER-A 
SINGLE INSTITUTION EXPERIENCE 
Scrase,C.D.*,Crosbie,J.,Laker,R.,Mackenzie,C.M.,Poynter,A.J.,James,H.V. 
& LeVay,J. 
Department of Clinical Oncology, The Ipswich Hospital NHS Trust, Suffolk, 
U.K. 
INTRODUCTION
Randomised data supports the role for conformal radiotherapy in the radical 
treatment of prostate cancer in achieving comparable tumour control with 
lower side effects when compared with conventional radiotherapy. In 
anticipation of these positive results, this institution opted for conformal 
radiotherapy for all patients to be treated by 3D conformal techniques in 
addition to those patients enrolled into the MRC RT01 randomised control 
trial. This programme has evolved over three years now, and we present our 
experience thus far.  
METHODS
Retrospective review of all patients treated with conformal radiotherapy with 
respect to tumour characteristics, use of hormones, treatment technique 
including outlining of tumour and normal tissue volumes, recorded acute and 
late toxicity and PSA failure. The RT01 trial definition of PSA>2 and ≥ 50%
rise from nadir was used for PSA failure. The tumour was outlined by the 
same clinician (CDS) in all but two cases. Inclusion of all or part of the 
seminal vesicles was determined according to risk formulae. Normal tissues 
were outlined by the same clinician or at least independently verified. The 
rectum was outlined according to standardised criteria. Toxicity was scored 
using the RTOG system. 
RESULTS
Between 1/99-12/01, 75 patients have been treated. Median follow-up 12.2
months. Clinical stages were T1(37%),T2(55%),T3(8%). PSA ranged from 
1.2-114 (median 16). 95% had neoadjuvant hormones, 12% receive adjuvant 
hormones. 25% received 74Gy.  Acute urinary toxicity 32%G2 8%G3. Acute 
rectal toxicity 40%G2 1.3%G3. Late toxicity thus far (where ≥ 3mo. follow 
up) bladder 6%G2 1.5%G3, rectal 10.8%G2 4.5%G3. No patients have 
developed G4 late toxicity. Late toxicity was predictable from DVH of 
normal tissues (>55% rectum received ≥ 95% TD). Latterly, high rectal doses 
would not be accepted and reduced dosing to the seminal vesicles (50-56Gy) 
a consideration. Six have biochemical failure. One patient has developed 
symptomatic local relapse.
SUMMARY AND CONCLUSIONS
Our preliminary data supports the decision to adopt conformal radiotherapy 
as definitive non-surgical treatment in the curative treatment of prostate 
cancer. The toxicity rate is low and PSA control at this early stage 
(particularly given the proportion who received neo-adjuvant hormones) 
favourable and compares well with published data from larger centres. With 
IMRT being implemented at other tumour sites in this institution, we feel 
well prepared for its incorporation into the prostate cancer treatment 
programme and the opportunity to join other dose escalation studies. 
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RADIOTHERAPY FOR BLADDER CANCER 
A. El-Modir*, D. Fairlamb
1
*Royal Shrewsbury Hospital, Shrewsbury and 
1New Cross Hospital, 
Wolverhampton, UK  
Objective: To characterize the patient population referred for radiotherapy 
for bladder cancer and to assess the effectiveness of radiotherapy in this 
population. 
Design: We retrospectively reviewed the medical records of 35 patients 
referred to the Deanesly Centre at New Cross Hospital between January 1997 
and December 1998 for radical radiotherapy for carcinoma of the urinary 
bladder. 
Material and Methods: The median age of the 35 study patients was 72 
years (range, 51 to 88), and the male:female ratio was 4:1. Two (5.7%) 
patients had T1 tumours, fifteen (42.8%) patients had T2 tumours, twelve 
(34.3%) patients had T3 tumours and six (17.2%) patients had T4 tumours. 
Of the 35 patients, 34 had transitional cell carcinoma and 1 patient had 
squamous cell carcinoma. Thirty (85.7%) patients had a grade 3 histology. In 
all patients, the whole bladder was treated with no attempt to treat the pelvic 
lymph nodes. The median total dose of irradiation was 51.5 Gy. 
Results: Local control of bladder cancer treated with radiotherapy alone was 
as follows: T1, two of two patients; T2, fourteen of fifteen; T3, seven of 
twelve; T4, three of six. Thus, the local control rate was 74%. The actuarial 
3-year cause specific survival for T1, T2, T3 and T4 tumours were 100%, 
60%, 33% and 17%, respectively. Several other factors, like age, grade, 
performance status and the presence of ureteric obstruction were important 
for the outcome. 70% of our patients experienced grade 1 acute intestinal and 
bladder toxicities, 10-14% had grade 2 toxicities but no grade 3 or 4 acute 
toxicities were seen. So far, 5 patients developed grade 1 late bladder toxicity 
and 1 patient developed grade 1 late bowel toxicity. 
Conclusion: This small series substantiates the effectiveness of radiotherapy 
in patients with carcinoma of the urinary bladder. 
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A PHASE I TRIAL OF CONFORMAL RADIOTHERAPY WITH 
CONCURRENT ONCE-WEEKLY GEMCITABINE FOR INVASIVE 
BLADDER CANCER 
Sangar VK
*, Lyons J, Logue J, Wylie J, Clarke NW & Cowan R. 
The Christie Hospital NHS Trust, Manchester, United Kingdom. 
This study examines the dose-limiting toxicity of weekly Gemcitabine given 
concurrently with conformal radiotherapy in bladder cancer. 
Eight patients with invasive TCC (T2-3) opting for organ preserving therapy 
were studied. Treatment comprised conformal radiotherapy (52.50Gy in 20 
fractions over 4 weeks) concurrent with once weekly i.v low dose 
Gemcitabine. The starting dose of 100mg/m
2 was escalated in 50mg/m
2
increments in successive cohorts. The principles of ICH Good Clinical 
Practice, the Declaration of Helsinki as well as local regulatory requirements 
were observed. 
Mean patient age was 69 years (8 males). All had invasive TCC (4 T2; 4 T3). 
Mean pre-treatment IPSS was 5.5 (1-13). Dose-limiting toxicity was 
observed in two patients receiving 150mg/m
2; Grade III Bowel (1) and 
Urinary (1) toxicity (Mean post-treatment IPSS 11.5). Six patients received 
100mg/m
2 with no bowel, genitourinary or haematological Grade II-IV 
toxicity; Mean post-treatment IPSS was 5.5. One of six did not complete 
Gemcitabine treatment due to a vascular event unrelated to treatment. Of the 
8 patients studied, so far 6 (4 at 100mg/m
2; 2 at 150mg/m
2) have been 
evaluated for outcome at 3 months by cystoscopy and MR Scan. Five of six 
showed a CR (3/4 at 100mg/m
2; 2/2 at 150mg/m
2). One patient (100mg/m
2)
without a CR underwent salvage cystectomy but died of progressive disease. 
The remaining patients are well (follow-up 2 ￿ 12 months). 
Low dose Gemcitabine (100mg/m
2) Chemoradiotherapy is well tolerated and 
may provide an alternative organ preserving strategy in invasive TCC. 
P107 
ACUTE MORBIDITY OF HIGH DOSE RATE PROSTATE 
BRACHYTHERAPY AND THE LEARNING CURVE ASSOCIATED 
WITH THE DEVELOPMENT OF THIS SERVICE IN THE UK
McCormack M, Beresford MJ, Birtle AJ, Rickards D, Emberton M, Payne 
HA. Meyerstein Institute of Oncology, University College Hospitals, London 
W1T 8AA 
Aim  To report the acute morbidity associated with the learning curve for 
developing a new service of high dose rate brachytherapy for carcinoma of 
the prostate in the United Kingdom. 
Introduction  Carcinoma of the prostate is the second commonest cancer in 
the UK with approximately 23,000 new cases and 10,000 deaths per year. 
The treatment options for those with localised disease are surgery or external 
beam radiotherapy. Despite encouraging results with permanent seed 
implantation and high dose rate (HDR) afterloading brachytherpay in the 
USA, the UK has been slow to follow this lead. Our HDR prostate 
brachytherapy programme was established in 1999. We describe changes in 
key variables and the associated acute morbidity in the first 15 patients 
treated. 
Methods  Patients with intermediate or high-grade prostate cancer who would 
benefit from dose escalation were selected. Entry criteria were any of: stage 
T2a-T3a, Gleason grade >6 or PSA >10, N0, M0. Patients were initially 
treated with the HDR boost. Applicator needles were inserted under general 
anaesthetic through a perineal template with the prostate visualised by 
transrectal ultrasound. The treatment volume was CT-planned using the 
PlatoTM system and the dose given using an iridium HDR afterloading   
MicroselectronTM machine. The prescribed HDR boost dose was 16.5 Gy in 
3 fractions over 2 days with a minimum interfraction interval of 6 hours. 
External beam radiotherapy (46 Gy in 23 fractions over 4.5 weeks) was given 
to a CT planned volume of the prostate and periprostatic tissues. 
Results  15 patients with an age range between 57 and 74 years (median age 
67 years) were treated with the HDR procedure. 53% had T3a disease. 73% 
were Gleason grade >8 and 60% had a PSA >20. The learning curve 
associated with the treatment was steep and was best demonstrated by a 33% 
reduction for overall treatment time on day one of the HDR procedure. There 
was also a reduction in time taken for the individual steps in the 
brachytherapy process (needle implant, CT scanning, planning and treatment 
delivery). This paralleled the reduction in man-hours for all members of the 
multidisciplinary team as skills developed. The risk of acute morbidity 
decreased with experience: reduction in the length of in-patient stay fell from 
14 to 3 days, duration of catheterisation fell from 11 to 2 days and duration of 
haematuria reduced from 10 to 0 days. These factors all varied in proportion 
to the number of bladder punctures seen at cystoscopy (15 to 0 punctures). 
Acute bowel toxicity was no different from external beam irradiation alone. 
Conclusion    HDR brachytherapy is initially time-consuming, but with a 
steep learning curve ￿ the duration of the procedure and the associated 
morbidity are shown to rapidly reduce. 
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A NOVEL TRI-SPECIFIC ANTISENSE OLIGONUCLEOTIDE (AO) 
TO THE INHIBITORS OF APOPTOSIS PROTEINS (IAPS) 
ENHANCES APOPTOSIS IN PC3 PROSTATE CANCER CELLS 
KR McEleny*
1, RWG Watson
1, K Williamson
2, RNT Coffey
1, J Fitzpatrick
1
1Dept of Surgery, Mater Misericordiae Hospital, University College Dublin, 
47, Eccles St, Dublin 7, Ireland 
2Dept of Pathology, Queen￿s University Belfast 
Introduction. 
The Inhibitors of Apoptosis (IAPs) block caspase-mediated apoptosis. 
Prostate cancer cells are inherently resistant to apoptosis and previous studies 
in our laboratory have demonstrated that the IAPs are over-expressed in 
prostate cancer. We used a tri-specific AO to c-IAP1, c-IAP2 and XIAP to 
determine if down-regulation of these IAPs would increase apoptosis in PC3 
cells. 
Materials and Methods 
Time and dose response experiments revealed that 6 hours of incubation with 
200nM of oligonucleotide and lipofectin resulted in optimum transfection 
conditions. These conditions were used to determine the effects on PC3 cells 
of IAP AO, scrambled AO and lipofectin alone. The end points were: percent 
apoptosis, (propidium iodide DNA staining using flow cytometry), cell 
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PAGE western blotting). 
Statistical analysis was performed using Student￿s t-test. 
Results   Data=Mean  –  StandardDeviation. 
  Control  Lipofectin  IAP AO  Scrambled AO    
% Apoptosis  3.8 ±   1.3  4.7 ±  1.8     7.3 ±  2.2*     4.4 ±  2.0   
Cell No. (% Control)  100 ±  16.2    77.9± 19.8  65.5 ±  26† 73.0 ±  13.3       
*p< 0.05 v all groups, †p< 0.05 v Control only, n=3 independent experiments 
The IAP AO significantly induced apoptosis (p=0.002) and reduced cell 
numbers (p=0.01) compared to untreated controls. Western blotting 
demonstrated a down regulation in the expression of c-IAP1, c-IAP2 and 
XIAP in IAP AO treated cells when compared to control cells.  
Conclusions 
The tri-specific AO enhanced apoptosis in PC3 cells by down-regulating IAP 
expression. Strategies that target IAP expression, thereby enhancing 
apoptosis, could lead to the development of new treatments for prostate 
cancer.  
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THE EFFECT OF EGF RECEPTOR TYROSINE KINASE 
INHIBITION USING ZD1839 (IRESSA) COMBINED WITH 
PHOTODYNAMIC THERAPY IN BLADDER CANCER 
Briggs CH
1,2*, Betts CD
2, O￿Flynn KJ
2, Moore JV
1, Clarke NW
2,3
1Paterson Institute for Cancer Research, Christie Hospital, Manchester 
2Department of Urology, Hope Hospital, Salford, Manchester 
3Department of Urology, Christie Hospital, Manchester  
INTRODUCTION  The EGF receptor is important in TCC and is a target for 
anti-cancer therapy.  The EGFR inhibitor ZD1839 (Iressa) has synergy with 
radiotherapy in TCC in vitro and reports in other cancers have shown that 
EGFR is involved in recovery following photodynamic therapy (PDT).  This 
study combines Iressa with ALA-mediated PDT to assess their combined 
effects on TCC in vitro.
METHODS  Survival of the bladder TCC line MGH-U1 and its 
radiosensitive clone S40b was determined following treatment with ALA 
PDT and Iressa/ALA PDT combinations.  Cells were exposed to 5mM ALA 
with or without Iressa (10mM for 24 hours) during exponential growth.  Cells 
were then exposed to light at 630nm and 20mW power.  Experiments were 
carried out in quintuplicate on at least 3 separate occasions.  Flow cytometry 
determined differences in cellular protoporphyrin IX (the active 
photosensitiser) and cell cycle between the 2 cell lines following ALA PDT 
and combination ALA/Iressa PDT, to identify factors which might account 
for variation in cell survival between the 2 cell lines. 
RESULTS  Clonogenic survival assays showed that both cell lines were 
sensitive to PDT alone, though MGH-U1 was significantly more-so than 
S40b (p<0.001).  This was explained by a 4-fold greater level of PpIX 
fluorescence in the MGH-U1 line.  Prior exposure to Iressa produced a 4-fold 
increase in cell death in the S40b cell line compared with the parent MGH-
U1 line (p<0.001).  However, there were no significant differences in PpIX 
fluorescence or cell  
cycle between the two cell lines following Iressa exposure which might 
account for the survival difference.   
CONCLUSIONS  Iressa (ZD1839) increases the sensitivity of TCC to ALA 
PDT, though a differential effect is seen in radiosensitive and radioresistant 
cell lines. This suggests that there may be a role for EGFR inhibition in 
superficial bladder cancer treatment with photodynamic therapy. 
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A PHASE II STUDY OF A MODIFIED MVAC REGIMEN IN 
LOCALLY ADVANCED AND METASTATIC UROTHELIAL 
CANCERS.  
A. G. Macdonald* and J. D. Bissett, ANCHOR Unit, Aberdeen Royal 
Infirmary, Aberdeen, U.K. AB25 2ZN. 
Background. The combination of methotrexate, vinblastine, doxorubicin and 
cisplatin (MVAC) is a highly effective regimen in the management of locally 
advanced and metastatic urothelial cancer, with response rates of 39-72%, 
and median survival times of 10-15 months reported
1,2,3. The activity of this 
regimen, however, comes at the expense of  considerable toxicity, with grade 
III/IV neutropenia seen in 80-90% of patients and grade III/IV mucositis seen 
in 10-22%.  
Objective. To evaluate a modified MVAC (mMVAC) regimen (designed to 
reduce toxicity and ease delivery of chemotherapy while maintaining dose 
intensity) in patients with locally advanced and/or metastatic urothelial 
cancers, in terms of toxicity, delivered dose intensity, response rate, 
progression-free survival and overall survival, within a single centre setting. 
Methods. Twenty-three patients with locally advanced or metastatic 
transitional cell or squamous cell carcinoma of the urinary tract were treated 
with a total of 87 cycles of mMVAC between 1996 and 2000. Methotrexate 
(30 mg/m
2), vinblastine (4 mg/m
2), doxorubicin (40 mg/m
2) and cisplatin (70 
mg/m
2) were given on day 1 of a 21-day cycle, for a maximum of six cycles, 
evaluating response after every three cycles. 
Results. The mean dose intensity for each agent was over 90% of that 
intended, with six patients requiring dose reduction and nine cycles requiring 
to be deferred for one week. The regimen was well tolerated with no grade 
III/IV mucositis seen and only 44% of patients experiencing grade III/IV 
neutropenia. There were two cases of neutropenic sepsis, but no treatment-
related deaths. The overall response rate was 50% (CR rate 15%, PR rate 
35%, SD rate 30%), median time to progression was 8.9 months and median 
survival was 11.9 months. Actuarial estimates for 1-year and 18-month 
survival are 48% and 42% respectively.  
Conclusions. Modified MVAC is an easily delivered regimen (necessitating 
a hospital visit only once every three weeks), which produces lower rates of 
mucositis and neutropenia than reported for classical MVAC, without 
obviously compromising response rates and survival in this phase II study. 
1. Sternberg CN, Yagoda A, Scher HI et al (1989). Cancer 64: 2448 
2. Loerher PJ, Einhorn LH, Elson PJ et al (1992). J Clin Oncol 10: 1066 
3. von der Maase H, Hansen SW, Roberts JT et al (2000). J Clin Oncol 17: 
3068.
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DO TERMINALLY ILL HAEMATOLOGY PATIENTS RECEIVE 
MORE INVASIVE TREATMENTS AND LESS PALLIATIVE CARE 
THAN OTHER PATIENTS? 
Fuller C
1*, Williams R
1, Stuart NSA
1, Whitaker R
2
1Department of Oncology, Haematology and Palliative Medicine, Ysbyty 
Gwynedd, Bangor, North Wales, and 
2Institute of Medical & Social Care 
Research, University of Wales, Bangor, North Wales. 
Background: Dying haematology patients present specific problems that 
may not be addressed within the guidelines for care of the dying patient.
1
Aims: To determine if haematology patients receive a different pattern of 
care in the last 12 days of their life compared to those with non-
haematological cancer. Setting: A combined haematology, oncology, and 
palliative care unit in a DGH hospital with shared in-patient beds and junior 
staff. On-site consultants in haematology, medical oncology and palliative 
care. Patients and methods: 75 deaths within the same unit (25 consecutive 
deaths in 3 patient groups; haematology, oncology and palliative care) were 
analysed retrospectively from February 2001. The last 12 days of life were 
examined and the following parameters were assessed: invasive interventions 
(venous blood sampling; intravenous antibiotics and fluids, chemotherapy; 
radiotherapy; blood and platelet transfusion and invasive diagnostic tests) and 
palliative interventions (palliative procedures; use of syringe driver and use 
of integrated care pathway for the dying patient). Results: The haematology 
patients received more invasive interventions in the last 12 days before death 
with significant differences in the median number of interventions (13 in 
haematology group; 4 in each of other 2 groups). However, the analysis 
failed to show any differences in the number of palliative interventions 
between the groups. Palliative care patients received slightly more palliative 
interventions than the other groups, but this did not reach statistical 
significance. Conclusions: In many haematological illnesses the patient 
would die without intensive supportive treatment which can sustain the 
patient over months or years. When this treatment is withdrawn the patient 
quickly deteriorates and death becomes inevitable. Identifying the time when 
such supportive treatment has become futile or over zealous is difficult. This 
study indicates that in haematology patients, but not in oncology or palliative 
care patients, invasive interventions continue until a short time before death. 
Further research is needed to determine if this is appropriate or is in 
agreement with the wishes of patients or their relatives 
2.
1 Working Party on Clinical Guidelines in Palliative Care. Changing Gear- 
Guidelines for Managing the Last Days of Life in Adults 1997-National 
Council for Hospice and Specialist Palliative Care Services 
2 Stedeford A. An indestructible patient. BMJ 2001; 323:57. 
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TOXICITY OF TEMOZOLOMIDE WITH RESPONSE MODIFIERS 
IN METASTATIC MALIGNANT MELANOMA 
P.Lorigan
1*, S.Danson
2, A.Clamp
2, J.Hodgetts
2, L.Lomax
2, L.Ashcroft
2,
M.R.Middleton
2, N.Thatcher
2.
1Weston Park Hospital, Sheffield, UK;
 2Christie Hospital, Manchester, UK. 
Temozolomide (TMZ) is an imidazotetrazine with a mechanism of action and 
efficacy similar to dacarbazine (DTIC). It is an ideal candidate for 
combination regimens as it is well-tolerated and orally bioavailable. This 
phase II, two-centre study used TMZ alone and combined with interferon-α
(IFN) or thalidomide (THAL).  181 patients with metastatic malignant 
melanoma were randomised to receive six cycles of TMZ 200mg/m
2 po 
eight-hourly for 5 doses q4w, or TMZ 200mg/m
2 po od for days 1-5 with IFN 
5 megaunits sc three times a week each week q4w, or TMZ 150mg/m
2 po 
(increased after 1 cycle to 200mg/m
2 if there was no haematological toxicity) 
for days 1-5 with THAL 100mg po od q4w. Toxicity data (all and grades 3 
and 4) is presented in the table.  
Adverse  Events TMZ  alone TMZ-IFN                 TMZTHAL
(% of patients)  all    3    4   all    3    4   all    3    4 
Nausea    43    4    0   59    4    0   50    6    0     
Vomiting    37    4    0   41    2    0   25    4    0 
Constipation  25    0    0   24    0    0   40    0    2  
Diarrhoea    12    0    0   13    0    0     2    0    0   
Alopecia      0    0    0     6    0    0   10    0    0 
Rash      6    0    0     9    0    0   23    2    0 
Pulmonary   16    0    0   20    6    4   21    2    4 
Fever    14    0    0   37#  2    0     6    2    0 
Lethargy    49    6    0   56    2    0   60    6    0 
Per. neuropathy    0    0    0     0    0    0     0    0    0 
Infection    20  12    4   17    9    0   12    4    0 
Anaemia    57    8    0   74#  2    6   33    2    0 
Leucopenia  45  20    6   57  13  13   31  12    0 
Thrombocytopenia  71  31    8   63  20  11   27  10#  
0#
Creatinaemia  10    0    0   13    0    0   10    0    0 
Bilirubin    14    0    2     7    0    0     6    0    0 
Alk Phos    39    4    0   26    0    0   25    0    0 
Transaminases  31    2    0   30    2    0   21    6    0 
(# = statistically significant) 
Treatment-related performance status was comparable between the three 
arms. Efficacy data is not yet mature but will be presented at the meeting. 
Conclusion: Of the 3 regimens tested the combination TMZ-THAL is the 
least toxic and the most promising. 
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ASSESSMENT OF RENAL FUNCTION IN OSTEOSARCOMA AND 
PERIPHERAL PRIMITIVE NEURO ECTODERMAL TUMOUR 
(PPNET) PATIENTS 
C Siller*, M Burniston
1, A Protheroe, S Picton
2.  Department of Medical 
Oncology, Cancer Research UK Clinical Centre, 
1Department on Medical 
Physics, 
2Paediatric Oncology Department, St James￿s University Hospital, 
Leeds, LS9 7TF. 
Occasionally patients with large solid tumours have very high initial 
glomerular filtration rate (GFR) as measured by isotope clearance techniques, 
which, with effective treatment falls to normal range with no obvious 
explanation.  This phenomenon was investigated further because of the 
importance of GFR to calculate drug dose and monitor renal function.  This 
retrospective study investigated the relationship between the serial GFR 
assessments made by serum creatinine and isotope clearance techniques. 
All patients with osteosarcoma and PPNET diagnosed over a 5-year period in 
the Paediatric oncology department were studied using a case note review.  
Treatment schedules, clinical course, isotope GFR, serum creatinine, and 
monitored episodes of renal dysfunction were documented.  
There were 36 patients with a median age at diagnosis of 16.8 years (range 
1.6 ￿ 23.6). 20 (56%) patients had a high initial GFR (females 
>130ml/min/1.73m
2 males >150ml./min/1.73ml/min/1.73m
2) and 18 of these 
fell to within normal limits with treatment.  There were 12 incidents of acute 
renal impairment as defined by CTC criteria grade 2 or above. Most of these 
episodes were attributed to dehydration or to the use of aminoglycoside 
antibiotics and in almost all cases GFR values subsequently returned to 
normal.  
Overall there was a poorer correlation between serum creatinine and isotope 
clearance in this group than in other reported populations (r=0.66) but there 
was a large inter-patient variability in agreement between the two techniques. 
Large variations in serum creatinine and therefore estimated GFR were noted 
during periods of intravenous fluid therapy. This highlights the need for 
careful selection of any serum creatinine assessment subsequently used for 
drug dose calculation. Samples must be taken whilst a patient is clinically 
stable and not on treatment.  
This audit describes the phenomenon of raised GFR but does not explain the 
cause. The role of isotope GFR and serum creatinine in monitoring renal 
function needs to be further defined through prospective studies.  
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RESULTS FROM A PILOT QUESTIONNAIRE OF GFR PRACTICE 
AMONGST ONCOLOGISTS IN THE YORKSHIRE REGION 
C Siller*, M Burniston
1, A Smith, T Perren, P Selby, A Protheroe. 
Department of Medical Oncology, Cancer Research UK Clinical Centre, 
1Department of Medical Physics, St James￿s University Hospital, Leeds, LS9 
7TF.  
The assessment of glomerular filtration rate (GFR) in the UK is challenging 
for cancer physicians.  A questionnaire was designed to investigate the 
practice of GFR assessment within the UK of oncology patients by 
oncologists, consultants and trainees, both clinical and medical.  The 
questionnaire was first piloted amongst oncologists in Yorkshire.  63 
oncologists were invited to participate in the survey.  Clinical oncologists 
were sent a letter with the questionnaire and invited either to fill in the 
questionnaire and send it back, or to submit it electronically.  Medical 
oncologists were invited by email to submit the form electronically.   30 
(48%) replies were received, 16 electronically and 15 by paper.  14 (37%) 
clinical and 16 (64%) medical oncologists replied.  All hospitals in Yorkshire 
where cancer patients are treated were represented by replies received. 
97% of oncologists made at least occasional use of serum creatinine estimates 
of GFR, with unanimous use of the Cockcroft-Gault algorithm. More patients 
had GFR assessments by measurement of serum creatinine than by isotope 
clearance techniques. Perceptions of the different techniques and their 
accuracies are very variable. Most replies suggested that measurement 
techniques are very accurate with 83% of responses suggesting errors of 10% 
or less. Creatinine clearance was suggested as a more accurate technique than 
serum creatinine by 63% of respondents but estimates of errors for both of 
these techniques ranged from 5% to 60%. 
 Most respondents believed that the presence of oedema (97%) and ascites 
(93%) might lead to problems in the assessment of GFR but few made any 
comments about action they would take in these circumstances. There was 
less agreement on the effect of pleural effusions, with only 67% stating that 
this could influence results. There was no consensus as to whether 
intravenous fluids could alter GFR. 
 Most oncologists treat at least some patients with GFR based dosing regimes 
but a variety of techniques are used ￿ serum creatinine, isotope tracer and 
creatinine clearance. There is no consensus that different techniques may be 
appropriate for these patients.  
 Most oncologists do not routinely drain their patients of any ascitic fluid 
before administration of carboplatin. The COIN guidelines on management 
of patients with renal damage do not appear to have been universally 
accepted with fewer than half of the respondents using them.  
Overall GFR measurements or estimates are widely used for patients with 
cancer. Practices vary considerably, there are no set guidelines as to which 
patients GFR is performed on or indeed the methods used. A revised GFR 
questionnaire will be distributed to oncologists nationally. 
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THE USE OF THE INTERNET AS AN INFORMATION RESOURCE 
FOR PATIENTS WITH CANCER
R Simcock, Sussex Oncology Centre, Brighton Health Care NHS Trust, UK 
Introduction  Enormous interest surrounds the use of the Internet as a 
medium for distributing information regarding healthcare. Many centres have 
dedicated resources towards providing information on the Internet although 
there remains comparatively little information on who the chief users of this 
information are. 
Method A questionnaire was issued to consecutive new patients registering 
at the Sussex Oncology Centre. Patients filled out the questionnaire 
immediately before their first appointment with an Oncologist. Patients were 
asked to select from a list information resources they had consulted and to 
rate their perception of the usefulness of those resources. Demographic 
information and information on access to Internet technology was also 
requested. 
Results 79 questionnaires were returned. 38 patients were male and the 
average age of the group was  65 years (25-82). Only 16 patients (20%) 
reported personal access to the Internet although a further 29 (37%) reported 
that their friends or family had access. 94% of the group had received 
information about their disease from some source. 91% received information 
from a doctor or nurse, 59% from books and leaflets and 25% from other 
media. 12 patients (15%) had found information from the Internet, 3 of them 
despite not having personal access. All patients seeking information from the 
Internet also sought information from books and leaflets and their doctors. 
Patients finding information from the Internet rated the usefulness of that 
information more highly than any other source except the information from 
doctors. Only one patient found information from the Internet "not useful". 
50% of those with personal access to the Internet had not used it to seek 
information related to their illness. The average age of patients using the 
Internet was 55 but all age groups were represented (25-82). 
Conclusions  In this group of patients a significant percentage used the 
Internet to seek information related to their disease and found the information 
useful  however information from doctors was rated as the most useful.
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A PROSPECTIVE AUDIT OF PERIPHERALLY INSERTED 
CENTRAL VENOUS CATHETERS (PICCS).  
MP Decatris
1*, K Jeffries
1, S Santhanam
1, A Thomas
2, S Khanna
1, S 
Vasanthan
1, A Benghiat
1, RP Symonds
1, K O￿Byrne
1 and WP Steward
1.
1Department of Oncology, University Hospitals of Leicester NHS Trust, 
Leicester LE1 5WW, UK and 
2Department of Oncology, Peterborough 
Hospital, Peterborough, UK. 
Aim PICC lines are virtually free from traumatic complications during 
insertion, easier to maintain than Hickman lines and are increasingly used to 
administer infusional chemotherapy in our unit. A prospective audit of PICC 
line insertions has been conducted to evaluate the incidence of complications 
in Oncology patients. 
Methods All PICC line insertions for the year 2001 were audited by 
completing a 6 page-long specifically designed form at the time of insertion 
including details of the procedure. Information on complications was 
collected and analysed retrospectively from the patients￿ medical notes. 
Results Out of 104 attempts there were 93 (88%) successful line insertions in 
88 patients (5 patients had 2 lines). Six lines were inserted under X-ray 
guidance. Median patient age was 61 (range, 18-80). A median of 2 cycles 
(range, 0-12) of chemotherapy was delivered during a total of 6,182 catheter-
days. The median PICC life was 51+ days (7-203). The main types of 
chemotherapy delivered were, cisplatin/5-fluorouracil (5-FU) (35%), De 
Gramont (24%) and oxaliplatin/5-FU (17%). Cannulation was easy in 80% of 
the cases. There were no major complications from insertion. 70% of patients 
had no catheter-related complications. Deep vein thrombosis (DVT) was seen 
in 5 cases needing removal of the line and treatment with Tinzaparin. Exit 
site infection was seen in 6 cases (5 definite, one possible) needing treatment 
with oral antibiotics. Coagulase negative staphylococcus septicaemia 
occurred in one neutropenic patient who required intravenous antibiotics and 
made a full recovery. 2 cases of systemic infection, possibly related to the 
lines, were seen; in one patient the line was blocked and removed and in the 
other cultures were negative but the line was eventually removed.  
Incidence DVT 
(Def+Pos) 
Infection
￿
(Def+Pos) 
Phlebitis 
(Def+Pos) 
   Line        Line 
Blocked  Migrated 
Fracture 
Cases
(% of  total) 
5+2
(5.4+2.1) 
6+3
(6.5+3.3) 
3+3
(3.3+3.3) 
6
(6.6) 
4
(4.3) 
4
(4.3) 
/1,000 
PICC-days 
1.1+0.3 1.0+0.5 0.5+0.5  1.0  0.7  0.7 
Def, definite; Pos, possible; 
￿includes exit site and systemic infection. 
Conclusion The incidence of catheter-related sepsis and other complications 
is low in comparison to other published data. The incidence of sepsis 
isconsiderably lower than that routinely seen with Hickman lines. This audit 
supports the increasing use of PICC lines for patients needing infusional 
chemotherapy. 
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ORAL ANTIBIOTICS AND EARLY HOSPITAL DISCHARGE FOR  
PATIENTS WITH LOW-RISK NEUTROPENIC FEVER WITH 
COMBINATION: A SINGLE-CENTRE EXPERIENCE 
H Innes*, A Ibrahim, A. Moss and E. Marshall, Clatterbridge Centre for 
Oncology, Wirral, Merseyside CH63 4JY 
Neutropenic sepsis is a potentially life-threatening complication of 
chemotherapy. In-patient therapy with broad-spectrum intravenous antibiotics 
has therefore become the standard of care for all patients. However, it is 
possible to identify criteria by which episodes of ’low-risk’ neutropenic fever 
can be identified. Two large trials
1,2 have demonstrated equivalence for 
combination oral antibiotics compared with intravenous regimens for in-
patient treatment of these ’low-risk’ episodes. In addition, we have shown
3
that for such patients oral antibiotics in conjunction with early hospital 
discharge for patients who remain stable after an initial 24hour monitoring 
period offers a feasible, safe and more convenient alternative when compared 
with conventional management. 
We have now adopted this approach as standard management of ’low-risk’ 
neutropenic fever in our cancer centre and here report our initial experiences 
with this policy. We have introduced a standardised care pathway for the 
treatment of neutropenic fever. Patients are treated with oral antibiotics 
(ciprofloxacin 750mg bd + co-amoxiclav 625mg tds for 5 days) if they fulfil 
the following criteria, as judged by the admitting doctor. i) 
haemodynamically stable, ii) not requiring intravenous fluids, iii) able to 
tolerate oral antibiotics, iv) absence of a clinically significant focus of 
infection and v) no allergies to the antibiotics. These patients are then 
reassessed on the morning following admission and are eligible for discharge 
if they have remained stable. Patients not fulfilling these criteria are treated 
with a standard in-patient intravenous regimen (ceftazidime). 
To date, 97 episodes of neutropenic fever have been treated according to this 
pathway. 52 episodes (53.6%) were treated with oral antibiotics. The median 
stay length for these patients was 36 hours (range 12hrs ￿ 11 days) and 41 of 
these (78.8%) resolved without changes to the antibiotic regimen or 
readmission. The remaining 11 episodes were all successfully salvaged 
without significant sequelae. Of these, only 1 had significant clinical 
deterioration (within the initial monitoring period) and 3 episodes required 
changes to antibiotics because of toxicity (vomiting and diarrhoea). Other 
toxicity was mild. 2 patients (3.8%) required readmission.   
In conclusion, our initial experience with this policy support our earlier 
findings that treatment of low-risk neutropenic fever with oral antibiotics and 
early hospital discharge is a realistic alternative to standard management. We 
will present updated results of our experience at the meeting. 
1Freifield A, Marchigiani D, Walsh T et al. New Eng J Med 341: 305-311, 
1999
2Kern WV, Cometta A, De Brock R et al. New Eng J Med 341: 312-318, 
1999
3Davies HE, Smith DB, O’Reilly SM et al. Proc Am Soc Clin Oncol abst 
2379, 2000
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AGEING & CANCER SUSCEPTIBILITY: IS SYSTEMIC FAILURE 
OF APOPTOSIS A FACTOR? 
Ruth Gilchrist*, Doug Easton, Emma McKenzie-Edwards, Diana M Barnes, 
Diana M Eccles, Audrey Ardern-Jones, Shirley V Hodgson, Paula M Duddy, 
Rosalind A Eeles and Richard S Camplejohn. Richard Dimbleby Dept. 
Cancer Research, Guys, Kings and St Thomas￿ School of Medicine, St 
Thomas Hospital London, SE17EH. 
Previously, we reported results of a three year study determining the value of 
rapid functional assays of p53 status in LFS and LFL families
1. The 
Apoptotic Assay measures the apoptotic response of human PBL to ionising 
radiation and highlights those individuals with a possible p53 defect; patients 
with p53 mutations are unable to produce an apoptotic response greater than 
30%. The final statistical analysis of the study, including breast cancer 
patients (n=243), controls (n=48) and cancer-free individuals with family 
history of cancer (n=64), has demonstrated an interesting phenomenon. We 
report that non-LFS/LFL individuals with breast cancer have a reduced 
apoptotic response versus controls (adjusted mean difference 5.74, p=0.005). 
134 of the 243 female breast cancer patients had radiotherapy or systemic 
therapy at various times prior to the assay being performed. However, the 
response for the group of patients receiving no therapy (mean response 40+/-
11% SD) was similar to that for the whole group (mean response 39+/-11% 
SD) and thus, therapy had no significant effect on apoptotic response. Several 
studies over the past five years report a reduced apoptotic response to DNA 
damage with increasing age in rodents
2. Until now, no such data were 
available in humans. Systemic failure of apoptosis could be one mechanism 
whereby breast cancer incidence rises sharply to a high constant rate at a 
genetically determined age
3. We report a markedly reduced apoptotic 
response with increasing age in all three sample groups (p=trend for age). 
Age of  Breast  Cancer-free with  Control. (n) 
 P=0.001  p=0.0001  p=0.04 
<30  48.9 (6)  47.9 (7)  52.4 (19) 
30-39  42.2 (61)  44.7 (18)  48.2 (20) 
40-49  37.8 (69)  40.6 (18)  43.7 (3) 
50-59  37.6 (76)  36.1 (14)  44.3 (5) 
>60  37.1 (31)  27.9 (7)  43.7 (1) 
The finding of a significant association between DNA-damage-induced 
apoptosis and breast cancer risk raises the possibility that apoptotic response 
is a marker of susceptibility to cancer and could form the basis of a predictive 
assay. 
References. 
1. RS Camplejohn, N Sodha, R Gilchrist, ME Lomax, PM Duddy, C Miner, P 
Alarcon-Gonzalez, DM Barnes and RA Eeles. 2000. British Journal of 
Cancer. 82(6), 1145. 
2. Polyak K, Wu TT. Hamilton SR, Kinzler KW, Vogelstein B. 1997. Cell 
Death Differentiation. 4, 242. 
4.  Peto J, Mack T. 2000. Nature Genetics. 26, 411 
P120 
AN AUDIT OF HYPERBILIRUBINAEMIA (hiB) ASSOCIATED 
WITH MALIGNANCY. 
F. Nussey * and M. Mackean.  Edinburgh Cancer Centre, Western General 
Hospital, Crewe Road, Edinburgh, EH4 2XU, Scotland. 
Introduction.  A number of patients (pts) with advanced solid tumour 
malignancy develop symptomatic jaundice within the last few weeks of life.  
This can be due to intrahepatic disease or obstruction of the biliary tract, for 
example by porta hepatis lymphadenopathy.  Relief of obstructive jaundice in 
primary biliary malignancy is well established.  However, our perception was 
that a number of pts with obstruction of the biliary tree due to advanced solid 
tumour malignancy undergo procedures (such as ERCP or PTC) aimed at 
relieving this with little benefit in terms of symptoms and at the expense of 
spending many of their last valuable days of life in hospital. 
Aims.  The primary aim of this study was to evaluate the success of 
interventions performed to relieve the symptoms of hiB in patients attending 
our centre.  Secondary aims included assessment of the number and type of 
investigations and interventions performed for the investigation and treatment 
of hiB, as well as examining the length of hospital stay and survival from the 
diagnosis of hiB.   
Materials and Methods.  Pts were identified from the clinical biochemistry 
database over the period 1/1/98 to 31/12/98.  All pts with a bilirubin 
recording of greater than 50µ mol/l were identified and case notes were 
examined for those pts known to the oncology directorate. Information 
relating to age, primary diagnosis, diagnosis of metastatic disease, 
biochemistry, investigations and interventions was recorded.  Survival from 
the date of hiB was calculated, and the number of nights spent in hospital was 
obtained from the patient management system. Pts with primary biliary 
malignancy were excluded.  Statistical analysis was performed using Excel 
97.
Results.  111 pts were identified, and notes were not available for 14.  Notes 
for 98 pts were examined.  The mean age was 59.9 years (35-79) and the 
mean time from primary diagnosis was 29.2 months (1-156). The majority of 
pts had either colorectal (34%) or breast (28%) primaries.   Imaging of the 
liver was performed in 43% of pts with hiB.  7 of 8 pts had successful 
procedures performed to relieve hiB, but in 5 of these PTC was required after 
failed ERCP.  The median survival of the intervention group from hiB was 
median 62.5 days (range 15-180) compared to median 45 days (range 1-395) 
in the others (p=0.42).  Those pts undergoing procedures did however spend 
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those who did not (median 9 (0-67) (p<0.05)).  
Conclusions. Pts undergoing an intervention to relieve obstruction as a cause 
of their hiB did not live significantly longer than those pts who did not.  They 
did however spend significantly more of their last weeks of life in hospital.  
Future. A care pathway designed to standardise investigation and 
management of these patients will be presented, with the aim of reducing 
hospital stay.  This will be implemented over a one year period and the 
results will be compared to those from the current audit. 
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WAITING TIMES AUDIT: ORGANISATION OF ONCOLOGY 
CLINICS ￿ HAVE WE GOT IT RIGHT?  
J.E Abraham ∗ ; L Roberts; R.J Benson; H.M Earl; J Singer.  Department of 
Oncology, Addenbrooke￿s Hospital NHS Trust, Hills Road, Cambridge CB2 
2QQ. 
Introduction; Patient-centred care should be the basis for organisation of 
oncology clinics. Have we fundamentally misunderstood what patients 
perceive to be most important when they attend clinics? The aims of the audit 
were:  
i)  To ascertain whether clinic scheduling addresses patients￿ own priorities. 
ii) To assess the influence of disease site or hospital location on clinic 
requirements. 
iii) To compare patients￿ and doctors￿ perception of actual consultation 
length. 
Methods; A questionnaire format was designed to address the following 
issues in 5 hospitals within the West Anglia Cancer Network (1 cancer centre 
and 4 cancer units): Q1) How long should your oncologist spend with you for 
your initial consultation? 
Q2) How long should your oncologist spend with you for your follow-up 
consultation? Q3) What is an acceptable delay between your diagnosis and 
initial consultation?
Q4)  Ideal organisation of oncology clinics would be; a) All clinics run 
punctually, you are seen within 1-2 weeks of diagnosis, but the time is strictly 
limited to 10-20 minutes. b) All clinics run punctually, you have longer 
consultation times e.g, 30-40 minutes, but there is a longer wait for the initial 
appointment i.e. 4 weeks. c) All clinic consultations are longer e.g. 30-40 
minutes, waiting times while in clinic maybe 1-2 hours, but you will be seen 
within 1-2 weeks of diagnosis. Questionnaires were distributed at registration 
in reception. The responses were assessed by hospital location and disease 
site. The study was completed over a 2 week period at each hospital, between 
07-10/01. 
Results: There were 345 assessable patient responses. 
Q1) and Q2) Most patients expected the Oncologist to spend 20 minutes 
(47%) on the initial consultation and 20 minutes (51%) on follow-up 
consultations. 
Q3) The majority expect to be seen within 2weeks of cancer diagnosis (mean 
value 60%) 
Q4) The majority (mean value 66%) preferred all clinics to be run punctually, 
be seen within 1-2 weeks of diagnosis but have shorter consultation times 
(option a). Overbooked clinics were the least popular (option c). There was 
no significant difference in responses seen between the patients with different 
tumour types or between the different hospitals. Oncologists￿ actual 
assessment of consultation duration  (which included review of medical 
notes, radiology and dictation etc) was 5-10 minutes longer, on average, than 
the patients￿ assessment.  
Conclusion:  Patients valued shorter waiting times in clinics more than 
prolonged consultations. Patients￿ perception of an acceptable initial 
consultation period (20 minutes) may underestimate the time required to 
convey all the relevant information. Alternatively a change to the clinic 
structure or a change in the methods used to convey relevant information may 
need to be considered. A re-audit including assessment of patient satisfaction 
regarding consultation length (pre & post consultation) is underway. 
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EARLY EXPERIENCES OF A REGIONAL RESEARCH NETWORK 
R.I. Harris* & P.Corrie, WACRN, Oncology Centre, Addenbrooke’s 
Hospital, Hills Road, Cambridge CB2 2QQ. 
The West Anglia Cancer Research Network (WACRN) was one of the first 
wave of cancer research networks to be established in 2001 with funding 
from the National Cancer Research Network (NCRN). The WACRN 
comprises a cancer centre at Addenbrooke’s Hospital (closely linked with 
Papworth Hospital) and cancer units at Bedford, Harlow, Hinchingbrooke, 
King’s Lynn, Peterborough and Bury St Edmunds.  The WACRN serves a 
population of 1.65 million with approximately 8000 registered cases of 
cancer per annum.
The NCRN funding for trials infrastructure has been used to appoint a 
Clinical Lead for Research, a Research Network Co-ordinator and a research 
nurse for each cancer unit.  Funds have been allocated for support services 
such as pharmacy, radiology, pathology and secretarial assistance.  Electronic 
databases to collect and manage trials recruitment data and trial 
chemotherapy data already existed at the cancer centre and these are being 
rolled out to the cancer units with master databases maintained at the centre. 
In 2000 (the baseline year for the WACRN), 612 (7.6%) patients were 
recruited into trials; 395 (4.9%) in national, 154 (1.9%) in commercial and 63 
(0.8%) in ’in-house’ trials.  NCRN adopted trials accounted for 279 (3.5%) of 
these patients.  For 2001, the corresponding figures were 542 (6.8%) for all 
trials, 394 (4.9%) in national, 79 (1.0%) in commercial and 69 (0.9%) in ’in-
house’ trials with 288 (3.6%) patients in NCRN trials.  In each year 29 NCRN 
adopted trials were actively recruited to in the WACRN. 
The presence of research nurses within the cancer units has had an immediate 
benefit in the quality, ease and timeliness of data collection for the databases 
and for data management staff at the centre who undertake much of the long 
term follow-up reporting.  At the West Suffolk Hospital, the first to employ 
an NCRN funded research nurse in April 2001, recruitment is being 
maintained in the face of closure of high recruiting trials.  For the period 
April - December the number of trials available for accrual doubled.   
Historically, many patients recruited at the units were referred to the centre 
for their treatment, however, it is now increasingly possible to offer patients 
trial entry and associated treatment locally. 
The target patient accrual per annum into NCRN adopted trials is 800 by 
April 2004.  Accruing 800 patients into NCRN adopted trials alone, whilst 
maintaining the WACRN’s current balance of national, international, 
commercial and local studies, represents a considerable challenge.  Although 
no increase in accrual to NCRN trials has been realised since April 2001 it is 
expected that the West Suffolk Hospital example will be repeated in other 
WACRN units and that after a period of consolidation increases will be seen. 
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GASTRO-OESOPHAGEAL CANCER AND THE TWO WEEK WAIT: 
DO THE PROTOCOLS WORK?  
Mr Paras Jethwa*, Dr Ann Keogh, Mr Ian Young
2, Ms Lina Stezhka
2, Mr 
Michael Hallissey, Mr John Fielding  
 Dept. of Surgery, University Hospital Birmingham, Queen Elizabeth. 
2Wolfson Computer Laboratory, University of Birmingham  
AIMS: To establish the validity of national referral criteria (DOH guidelines) 
for gastro-oesophageal cancer and adherence to these criteria by primary 
healthcare physicians. 
METHODS: A prospective audit of the outcome of referrals made to our 
centre was performed. A standard referral form was provided to local General 
Practitioners’ that records criteria for direct assess endoscopic referral and 
allows classification as Urgent or Non Urgent. Our unit uses a computer 
algorithm to reclassify priority using the criteria supplied on the referral 
form. All referrals categorised as urgent by their general practitioners were 
given an appointment within two weeks. General Practitioners’ classification 
was compared with that of the computer algorithm. 
RESULTS: During the ten month period of our audit 1169 upper GI 
endoscopies were performed following open access referral. 
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Group 
No. Of New 
Cancer Cases 
% 
Incidence 
Non Urgent/Non 
Urgent 
253 1  0.4 
Non Urgent/ Urgent  625  17  2.7 
Urgent/ Non Urgent  62  3  4.8 
Urgent/ Urgent  229  21  9.2 
Total  1169  42  3.6 
 
Of the referrals received by our unit primary healthcare physicians 
incorrectly coded 58.7% of cases. Prioritisation using the guidelines 
algorithm identified 38 of 42 cancers during this period. Data entry errors 
resulted in two of the three malignancies identified in the urgent/non urgent 
group being incorrectly classified. Correct input would have increase pick up 
in the urgent/urgent group from 9.2% to 10%. 
Conclusions: Despite initial scepticism adherence to the National criteria for 
urgent endoscopic referral is associated with a high incidence of diagnosis of 
malignancy. This study highlights the benefit to the patient of correct 
classification. 
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WORKFORCE PLANNING IN BREAST CANCER – A LOOK TO 
THE FUTURE 
AM Thompson* (1, 3), M Conroy (2), T Crilly (2), G Needham (3).  
(1) Department of Surgery and Molecular Oncology, University of Dundee, 
Dundee DD1 9SY, (2) Conrane Consulting, 116 Pepys Road, London SW20 
8NY, (3) Scottish Workforce Planning Group, Scottish Executive, 
Edinburgh. 
 
The management of women with breast problems, including cancer, is 
multidisciplinary, involving diagnostic, therapeutic, inpatient and outpatient 
facilities. The Tayside and Fife regional service has integrated the screening 
(for women age 50-64) and symptomatic (women of all ages) services and 
delivers breast services for 360 women with newly diagnosed cancer each 
year at 2 sites.  
Aim: to model future workforce requirements based on current practices and 
projected demand and to examine the effect of changes in working practice. 
Methods: for workforce planning, a baseline statement of staffing and 
workload was drawn up in consultation with all staff groups. The current 
relationship between staffing and workload (productivity) was then derived 
and the scope for changes in working practice, including improved 
productivity, within the current establishment laid out. A forecast growth of 
20% in breast cancer patients in the service to 2014, (Chetty, 2001), was used 
to examine the effects on the workforce both for the current productivity ratio 
and secondly taking into account the changes in roles particularly for breast 
clinicians and nurses. Projecting the data for Tayside onto a Scottish 
workforce allows a prediction of the likely increase in workforce required 
(excluding replacement of current staff retiring or the impact from changes 
elsewhere in the service). 
Results: The two major groups requiring expansion are nurses (breast care 
nurses and non-specialist nurses), where 26 whole time equivalents will be 
required across Scotland, and doctors where 17 whole time equivalent 
clinicians in a range of specialties will be needed. How these staff would be 
distributed across a geographically wide area remains to be seen.  
Discussion: There are implications for the effects of developing the breast 
service on other parts of the health service which may be dependent on the 
same workforce pool in terms of recruitment, training and retention, 
developing the radiographer and nurse practitioner roles, flexibility for 
clinical contact roles (skill mix) and management.  
These productivity and workload developments take the current practices into 
account from the point of view of patient and staff numbers, but do not 
necessarily address the issue of the quality of service delivered. Gradual 
changes in imaging practices, operating practices, IT developments with their 
implementation and the delivery of tailored chemotherapy may well 
significantly influence working practices in the next decade. Quantum 
changes such as increasing the age range of conventional breast screening for 
women above 70 years or below 50 years of age are also likely to have a 
significant impact on workforce requirements. 
Conclusions: this type of detailed analysis of the current workforce, 
modelling the effects of changes in working practice and projected increased 
demands may be useful in  service planning in a range of speciailities. 
Reference: Chetty, U. Breast Cancer. p105-114. In: Scottish Executive 
Health Department (2001). Cancer Scenarios: an aid to planning cancer 
services in Scotland in the next decade. Edinburgh, The Scottish Executive. 
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TRANS-TASMAN RADIATION ONCOLOGY GROUP (TROG) 
DEVELOPMENT 1989-2002, AND RESULTS OF TRIALS 
Prof Jim Denham*  (TROG Group Co-ordinator) Newcastle, NSW, Australia 
Dr David Lamb* (TROG Scientific Committee Chair) Wellington, New 
Zealand 
A/Prof David Ball (TROG President) Melbourne, Victoria, Australia 
Ms Olga Kovacev (TROG Senior Operations Manager) Newcastle, NSW, 
Australia 
 
The Trans-Tasman Radiation Group is a research organisation that was 
founded in 1989 by the presenters and others ‘to foster and promote the 
design and execution of high quality clinical studies which address 
radiotherapeutic management issues, particularly those that require multi-
institutional participation’.  
Thirteen years later, a critical assessment is made as to whether or not the 
group has been successful in achieving this goal. 
TROG now has a membership of 92 out of 165 practising radiation 
oncologists in Australia and New Zealand, and 32 out of 36 radiation 
treatment centres have at least one TROG member. 3800 patients have been 
entered into clinical trials.  
The important landmarks in the development of the group will be 
summarised. The main findings of phase III trials will be presented, including 
some unpublished data. Finally, the future direction of the group will be 
outlined.  
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RECRUITMENT OF PATIENTS WITH CANCER INTO 
RANDOMISED CLINICAL TRIALS: EXPERIENCE AT A SMALL 
CANCER CENTRE 
A. El-Modir
*, R. Agrawal, V. King, M. Adams, H. Moore 
Department of Clinical Oncology, Royal Shrewsbury Hospital, Shrewsbury, 
UK  
 
Background: Although many oncology patients are eligible to participate in 
clinical trials of cancer treatment, only between 5 and 7% of eligible patients 
currently enter clinical trials in the UK. Time pressures, lack of funding and 
support staff, especially in small cancer centres and units, are among the 
reasons for this. 
Methods: From our database, we reviewed all the patients referred to our 
centre and identified those eligible for entry into clinical trials and whether 
they have been offered  entry into trials. We have also studied the impact of 
the establishment of a clinical trials unit on our recruitment figures. 
Results: 4183 new patients referred to our unit between 1998 and 2001. 723 
(17.3%) were deemed eligible for entry into clinical trials. 583 (80.6%) of the 
eligible patients agreed to enter clinical trials. 94 patients were entered into 
more than one trial. The majority of patients who declined entry into trials 
did not state a reason; some patients did not want to have chemotherapy; a 
small proportion were worried about “randomisation” and few patients stated 
that they did not want to be “guinea pigs”. Our trial recruitment increased 
over 400% since the establishment of a clinical trials unit with dedicated staff 
to support clinical trials. 
Conclusion: Clinical trials are essential for the evaluation of different cancer 
treatments.  
All oncology centres should establish a clinical trials unit with dedicated staff 
if recruitment into trials to be increased. The extra costs of clinical trial 
participation must be recognised.  
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IMPLEMENTING THE SCOTTISH CANCER STRATEGY  
Dr Anna Gregor, Lead Clinician for Cancer Services in Scotland, Mrs 
Elizabeth Porterfield, Cancer Services Co-ordinator and Elaine Wilson, 
Implementation Manager* Cancer Team, Scottish Executive, St Andrew￿s 
House, Regent Road, Edinburgh EH1 3DG 
The Publication of Cancer in Scotland: Action for Change signalled a 
renewed drive to tackle cancer and the causes of cancer in Scotland.  An 
investment of £40 million over 3 years commencing 2001was dedicated to 
support the implementation of the strategy on top of existing national and 
local investment plans.  The focus of the strategy is on improving diagnosis, 
treatment and care through innovation and spreading good practice.  Three 
Regional Cancer Advisory Groups (RCAGs) have been created (North, South 
East and West) to improve the planning and design of local services.   
Key features of the strategy include: by October 2001 urgent referrals for 
breast cancer to begin treatment within one month of diagnosis; by 2005 
maximum wait from urgent referral to treatment for all cancers will be two 
months; managed clinical networks in place for all cancers by 2002, by April 
2002 a major programme of service redesign will be in place. 
The first RCAG￿s annual investment and implementation plans were 
published last November totalling £10.7million.  This first wave of 
investment included funding for more than 130 extra doctors, nurses and 
other specialist health professionals and vital cancer equipment such as 
scanners.  This was all aimed at building capacity to secure more rapid 
diagnosis and reduce waiting times, improve access and quality of care and 
improved access closer to home or at home.  But the Cancer Strategy is not 
just about money it is also about working in partnership and making the best 
use of the resources that we have. 
An implementation framework is being developed to drive forward and 
monitor the implementation of Cancer in Scotland.  The RCAGs will report 
their progress on implementing their investment plans and achieving the 
targets set out in the strategy on a 6 monthly basis.  This presentation reports 
on the implementation of the first 6 months to March 2002. 
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AUDIT OF CANCER PATIENT ENTRY TO CLINICAL TRIALS 
J Shaw*, H Cornwell, L Koncewicz, I Inman, P Corrie. Cambridge Cancer 
Trials Team, Oncology Centre, Addenbrooke￿s NHS Trust, Cambridge, CB2 
2QQ, UK. 
A retrospective audit of cancer clinical trial accrual rates was undertaken at 
Addenbrooke￿s Oncology Centre. The data presented encompasses new 
patient referrals for breast, gastrointestinal, ovarian, lung and renal cancers 
and melanoma to oncologists working in the centre between January 1
st and 
December 31
st, 2001. For all these disease sites, regular multi-disciplinary 
team meetings take place, allowing patients to be screened for eligibility to 
current clinical trials. Clinicians were responsible for offering patients 
clinical trial entry at consultation. Our data was obtained from various 
sources, primarily the disease site specific databases, which hold a limited 
amount of information on trial accrual. The results are summarised in the 
table below: 
  Breast  GI  Ovary Lung Melanoma Renal TOTAL 
New 
patient 
referrals 
408 200 186  81  66  7  948 
Patients 
offered 
trial 
entry 
90 56 12  19  20  2 199 
(21%)  
Patients 
entered 
72 35  5  9  16  2 139   
(15%) 
Patients 
declined 
18 21  7  10  4  0 60   
(6%) 
Our findings that 15% of patients entered a clinical trial compare favourably 
with similar studies by Spiro et al.
1 and Maughan et al.
2 who reported 11.7% 
and 4.8% patient accrual, respectively. However, the accuracy of our audit is 
limited by a failure to capture all pertinent information. For example, we do 
not know the percentage of potentially eligible patients who were not offered 
a trial by clinicians, the percentage of patients for whom no trial was 
available, or the percentage of consenting patients who ultimately failed to 
meet the trial inclusion criteria (screening failures). Furthermore, we would 
like to know more about patients who decline trial entry, especially their 
reasons for doing so. From January 2002, patient databases have been 
modified and paper proformas implemented to collect additional information 
to address the shortcomings of this audit. A future audit should help to 
identify possible barriers, such as trial availability, eligible patients not 
offered trial entry, and patient perceptions, that need to be addressed in order 
to improve patient accrual to clinical trials.   
1.  Spiro SG, Gower NH, Evans MT, Facchini FM, Rudd RM. Thorax 
2000; 55:463-5 
2.  Maughan TS, Branston L, Batt LA, Shankland SH. Br J Cancer 2000; 
83 S1:2 
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THE DETECTION OF EARLY p53 MUTATIONS IN COLORECTAL 
POLYPS USING THE RESTRICTION SITE MUTATION ASSAY 
*GL Williams
1,2, GJS Jenkins
2, JM Parry
2 and J Beynon
1
1Department of Colorectal Surgery, Singleton Hospital, Swansea, UK 
2School of Biological Sciences, Swansea University, Swansea, UK. 
INTRODUCTION: Most sporadic colorectal carcinomas are derived from 
precursor lesions known as polyps. This theory correlates well with the 
molecular biology of  neoplastic progression which depends on certain gene 
mutations. Heavily implicated are APC, K-ras and p53. The tumour 
suppressor gene p53 is thought to exert its effect late on in polyp progression 
rather than at initiation. The Restriction Site Mutation (RSM) assay selects 
mutated sequences at the molecular level hence microdissection of the tissue 
is unnecessary to enrich the mutant cell population. Mutations of p53 are 
detectable, even if the cells carrying such mutations are present within an 
excess of normal cells (sensitivity of 1 mutant sequence amongst 10,000-
100,000 normal sequences). The aim of this study was to use the RSM assay 
to detect whether early p53 mutations were detectable in colorectal polyps. 
METHODS: Polyps were obtained from different patients at routine 
colonoscopy. DNA was extracted by a high salt precipitation method and 
then amplified by PCR following restriction enzyme digestion by msp1. This 
enzyme was used to look specifically at one of the major p53mutational 
hotspots for colorectal neoplasms: codon 248. Following DNA analysis by 
RSM and RFLP, all suspected mutants were sequenced. 
RESULTS: Polyps from 55 patients were analysed for codon 248 mutation. 
Mutations were found in 4 of the 55 polyps. There were no correlations 
between these four and severity of dysplasia, histological type, nor with size. 
Two polyps had a G:A mutation at codon 248, while the other two displayed 
C:T mutations. 
CONCLUSION: We have been able to show with the aid of a very sensitive 
mutation detection system that mutations of p53 do occur at an early stage in 
the adenoma to carcinoma sequence. The fact that the RSM assay has 
detected p53 mutations in different types of polyps may be of benefit to 
further research into why certain polyps and not others progress to 
carcinoma. This could become important for patient follow up.  
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MOST MUTATIONS OF THE APC TUMOUR SUPPRESOR GENE IN 
SPORADIC COLORECTAL CANCER ARE TRANSVERSIONS 
*GL Williams
1,2, GJS Jenkins
2, JM Parry
2 and J Beynon
1
1Department of Colorectal Surgery, Singleton Hospital, Swansea, UK 
2School of Biological Sciences, Swansea University, Swansea, UK. 
INTRODUCTION:  The Adenomatous Polyposis Coli (APC) gene is heavily 
involved in sporadic colorectal carcinogenesis. APC mutations are the 
earliest known genetic alterations in progression to colorectal cancer and 
have been found in aberrant crypt foci and small adenomas. It is therefore no 
surprise that mutations of APC are thought to initiate the potential path to 
cancer. Certain types of gene mutations are thought to be due to differing 
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